Citius Oncology (CTOR) Non-Current Assets (2022 - 2026)
Citius Oncology (CTOR) posted quarterly Non-Current Assets of $71.3 million for Q1 2026, down 2.89% year-over-year from $73.4 million in Q1 2025, and down 2.13% quarter-over-quarter from $72.8 million in Q4 2025.
Citius Oncology (CTOR) Non-Current Assets (2022 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Non-Current Assets for 5 consecutive years, with $71.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 2.89% year-over-year to $71.3 million; the TTM figure through Mar 2026 stood at $290.9 million (up 8.0% YoY), while the FY2025 annual figure was $73.4 million, changed 0.0% from the prior year.
- Non-Current Assets declined to $71.3 million in Q1 2026 per CTOR's latest filing, from $72.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $73.4 million in Q3 2024 and bottomed at $40.0 million in Q3 2023.
- Historically, Non-Current Assets has averaged $66.2 million across 5 years, with a median of $71.9 million in 2023.
- On a YoY basis, Non-Current Assets climbed as much as 83.5% in 2024 and fell as far as 29.16% in 2024.
- Citius Oncology's Non-Current Assets stood at $67.8 million in 2022, then climbed by 7.01% to $72.6 million in 2023, then climbed by 1.15% to $73.4 million in 2024, then slipped by 0.78% to $72.8 million in 2025, then dropped by 2.13% to $71.3 million in 2026.
- Business Quant data shows CTOR's Non-Current Assets at $71.3 million in Q1 2026, $72.8 million in Q4 2025, and $73.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Citius Oncology | 80.25 Mn | 80.25 Mn | 1.00 Mn | 69.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 71.28 Mn |
| Dec 31, 2025 | 72.83 Mn |
| Sep 30, 2025 | 73.40 Mn |
| Jun 30, 2025 | 73.40 Mn |
| Mar 31, 2025 | 73.40 Mn |
| Dec 31, 2024 | 73.40 Mn |
| Sep 30, 2024 | 73.40 Mn |
| Jun 30, 2024 | 49.15 Mn |
| Mar 31, 2024 | 48.58 Mn |
| Dec 31, 2023 | 72.57 Mn |
| Sep 30, 2023 | 40.00 Mn |
| Jun 30, 2023 | 69.39 Mn |
| Mar 31, 2023 | 68.57 Mn |
| Dec 31, 2022 | 67.81 Mn |